NEW DELHI, June 22 (Xinhua) - Onye na-emepụta ọgwụ mgbochi India Bharat Biotech's Covaxin egosila nrụpụta 77.8% na nnwale nke III, ọtụtụ mgbasa ozi mpaghara kwuru na Tuesday.
"Bharat Biotech's Covaxin bụ pasent 77.8 dị irè n'ichebe megide COVID-19, dịka data sitere na ule nke III nke emere na ndị sonyere 25,800 n'ofe India," ka akụkọ kwuru.
Ọnụego nrụpụta ahụ pụtara na Tuzdee ka kọmitii ọkachamara na-ahụ maka isi okwu (SEC) nke onye na-ahụ maka ọgwụ na India (DCGI) zutere ma kparịta nsonaazụ ya.
Ụlọ ọrụ na-emepụta ọgwụ enyefela data nnwale nke III maka ọgwụ mgbochi na DCGI na ngwụcha izu.
Akụkọ kwuru na a na-atụ anya na ụlọ ọrụ ahụ ga-enwe nzukọ "mbụ nrubeisi" na ndị isi Healthtù Ahụ Ike ,wa na Wednesde, iji kparịta ụkpụrụ maka ntinye ikpeazụ nke data na akwụkwọ achọrọ.
India bidoro ịgba ọgwụ mgbochi ọnụ megide COVID-19 na Jenụwarị 16 site na ịnye ọgwụ mgbochi abụọ emere na India, ya bụ Covishield na Covaxin.
Ụlọ ọrụ Serum Institute of India (SII) na-arụpụta AstraZeneca-Oxford University's Covichield, ebe Bharat Biotech esorola ndị Indian Council of Medical Research (ICMR) na-emepụta Covaxin.
Ewepụtala ọgwụ mgbochi Sputnik V nke Rọshịa mere na mba ahụ.Enditem
Oge nzipu: Jun-25-2021